AMLX NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Amylyx Pharmaceuticals Inc · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 20.31 USD
10.3% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 32.0% above the Trend Line and sits at 95.3% of its 52-week range. The latest completed week returned 10.3%, after a 11.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 46/100 conviction, while the latest news-sentiment score is 51/100. Near-term considerations: price is close to its 52-week high; earnings are due in 5d.

Setup score 74 out of 100
Latest Close 20.31 USD 31 Jul 2026
1W Return 10.3% latest completed week
4W Return 11.2% short-term follow-through
12W Return 37.9% quarterly tape
Trend Breadth 94.2% 49 of 52 weeks active
Volume Ratio 1.8x vs 13-week average
What is working
  • The trend backdrop is active with a 7-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 1 reversal markers appear in the recent smart-money tape.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 10.3% Latest completed week; four-week move 11.2%. Indicator stack 76/78 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 46/100 conviction; expected move 50.9%. News sentiment 51/100 52 relevant articles in the latest sentiment read. Event risk 5d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 32.0% above the Trend Line and sits at 95.3% of its 52-week range. The latest completed week returned 10.3%, after a 11.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.8x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.6712-week average 0.55

12-week confirmation

Trend active9/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership7/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.67Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers11 reversal markers

No recent accumulation markers. 1 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 11.2% over four weeks, 37.9% over 12 weeks, and 163.3% over one year. The current trend has remained active for 7 consecutive weeks.

Performance by holding period

1W10.3%
4W11.2%
12W37.9%
26W42.1%
52W163.3%
Active trend streak7 weeks
Active weeks in one year49
Trend breadth94.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.83Latest activity-pressure read.
Pressure change167.1%Four-week change in activity pressure.
Leadership32.44Latest relative-leadership reading.
RS change61.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 67% Model confidence 64%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength73/100Blend of value, momentum, and quality. Underlying universe rank 28; rank 1 is best.
Value61/100Relative valuation strength. Underlying universe rank 40; rank 1 is best.
Quality60/100Profitability and accounting quality. Underlying universe rank 41; rank 1 is best.
Momentum61/100Medium-term price momentum. Underlying universe rank 40; rank 1 is best.
Growth61/100Revenue and earnings growth. Underlying universe rank 40; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-6.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-223.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-0.5%
Net share repurchases relative to market value.
Shareholder yield
-0.5%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

AMLX shows volatility options pressure with a 46/100 conviction score, put-call volume ratio of 1.40, expected move of 50.9%, and Sharemaestro trend signal active.

Conviction46/100
Expected move50.9%
Put/call volume1.40
Pressure-13
Speculation37
Volatility96
Trend agreement87
Open options detail
Insider activity6 / 2

6 acquisitions and 2 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment51/100

Weighted news tone is neutral across 52 relevant articles.

10 positive · 35 neutral · 7 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings5dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move50.9%Nearest-chain priced movement where available.
52-week drawdown-3.0%Distance below the 52-week high.
13-week volatility7.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+13.5%Week of 26 Jun.
Worst week-9.8%Week of 15 May.
Latest week+10.3%Week of 31 Jul.

Shape of recent returns

Strong gains9
Modest gains5
Flat weeks0
Modest losses6
Sharp losses6
Recent vol7.1%13-week weekly-return volatility.
Base vol7.8%52-week weekly-return volatility.
Up/down split30/22Count of positive and negative weeks in the 52-week window.
Average skew7.8% / -5.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape71/100

Trend, activity pressure, participation, and risk combine to a 71/100 tape read.

 Indicator analysis59/100

Latest 12-week confirmation: trend 9/12, activity pressure 6/12, relative leadership 7/12.

Activity pressure 0.67; 1 reversal markers Factors63/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 75; Small Cap Core rank 47 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options58/100

AMLX shows volatility options pressure with a 46/100 conviction score, put-call volume ratio of 1.40, expected move of 50.9%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 50.9% Sentiment51/100

Weighted news tone is neutral across 52 relevant articles.

Amylyx Pharmaceuticals Inc (AMLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages Insiders6 / 2

6 acquisitions and 2 disposals in the latest 180-day insider tape.

 Earnings5d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202620.31 USD10.3%15.39 USD9.72 USD0.8332.4413.4MOn
24 Jul 202618.41 USD3.7%15.09 USD9.73 USD0.6222.358.1MOn
17 Jul 202617.75 USD-0.1%14.89 USD9.76 USD0.6517.366.7MOn
10 Jul 202617.77 USD-2.7%14.70 USD9.79 USD0.4913.675.8MOn
3 Jul 202618.27 USD2.7%14.54 USD9.82 USD0.3120.128.5MOn
26 Jun 202617.79 USD13.5%14.40 USD9.84 USD-0.1219.5111.8MOn
19 Jun 202615.67 USD7.4%14.31 USD9.86 USD-0.561.796.5MOn
12 Jun 202614.59 USD9.5%14.28 USD9.91 USD-0.73-1.647.8MOff
5 Jun 202613.32 USD-7.2%14.21 USD9.97 USD-0.84-7.297.3MOff
29 May 202614.35 USD5.7%14.18 USD10.05 USD-0.62-3.822.7MOff
22 May 202613.58 USD2.2%14.17 USD10.12 USD-0.32-5.495.6MOn
15 May 202613.29 USD-9.8%14.19 USD10.19 USD0.05-5.656.0MOn
8 May 202614.73 USD-8.0%14.24 USD10.27 USD0.575.236.7MOn
1 May 202616.01 USD-6.0%14.23 USD10.36 USD0.8222.004.9MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.